EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unveiling the complexity of neurofibromatosis type 1: Innovations in genetic understanding and clinical management. A narrative review

Aurora Jurca, Simona Pop, Claudia Maria Jurca, Cosmin Mihai Vesa, Alexandru Daniel Jurca

Biomedical Papers · 2025

DOI: 10.5507/bp.2025.011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomedical Papers, 2025. Verfasst von Aurora Jurca und 4 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biomedical Sciences, University of Oradea, Oradea, Romania. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Genes, Neurofibromatosis 1. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by mutations in the NF1 gene. The most important signs are café-au-lait spots, intertriginous freckling, and neurofibromas. The disease has a progressive course, the penetrance is almost complete, and reduces life expectancy by approximately 15%. This review examines the current literature, including NIH (National Institute of Health) diagnostic criteria, genetic testing, genotype-phenotype correlations, and emerging therapies. Genetic testing has improved diagnostic accuracy, particularly for age-dependent clinical features. The genotype-phenotype correlation in NF1 underscores that specific genetic alterations, such as large deletions in the NF1 gene, are frequently linked to more severe clinical outcomes. These deletions often result in early onset of symptoms, a higher frequency of tumor development, and increased tumor burden, all of which contribute to a more complex clinical course. Consequently, individuals with these genetic changes require intensive and continuous monitoring to manage potential complications and prevent further health deterioration. Advances in therapies such as MEK inhibitors offer hope for inoperable plexiform neurofibromas, while surgery remains the primary option for localized tumors, despite the risk of recurrence. Multidisciplinary care and genetic advancements are crucial for improving the prognosis and quality of life of patients with NF1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Genes, Neurofibromatosis 1HumansGenetic TestingNeurofibromin 1Genetic Association StudiesMutation

Stichwörter der Autor:innen

MEK inhibitorsNF1 genegenotype-phenotype correlationneurofibromatosis type 1

Substanzen

Neurofibromin 1

Autor:innen und Institutionen

  • Doctoral School of Biomedical Sciences, University of Oradea, Oradea, Romania.
  • Department of Psycho-Neuroscience and Recovery Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
  • Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.

Zitieren

APA

Jurca, A., Pop, S., Jurca, C. M., Vesa, C. M., & Jurca, A. D. (2025). Unveiling the complexity of neurofibromatosis type 1: Innovations in genetic understanding and clinical management. A narrative review. Biomedical Papers. https://doi.org/10.5507/bp.2025.011

Vancouver

Jurca A, Pop S, Jurca CM, Vesa CM, Jurca AD. Unveiling the complexity of neurofibromatosis type 1: Innovations in genetic understanding and clinical management. A narrative review. Biomedical Papers. 2025. doi:10.5507/bp.2025.011

BibTeX
@article{Jurca2025,
  author = {Jurca, Aurora and Pop, Simona and Jurca, Claudia Maria and Vesa, Cosmin Mihai and Jurca, Alexandru Daniel},
  title = {Unveiling the complexity of neurofibromatosis type 1: Innovations in genetic understanding and clinical management. A narrative review},
  journal = {Biomedical Papers},
  year = {2025},
  doi = {10.5507/bp.2025.011}
}
Kostenlos starten →